Akorn, Inc. Announces Second Product Approval For Diltiazem Hydrochloride Injection
28 Luglio 2006 - 1:00PM
Business Wire
Akorn, Inc. (AMEX:AKN) today announced that it has received a
second ANDA approval for Diltiazem Hydrochloride Injection, 5mg/mL
in 5 and 10 mL vials. The product will be manufactured in the
Decatur, IL facility, and is the eighth product approval received
by Akorn this year. Arthur S. Przybyl, Akorn's President and Chief
Executive Officer stated, "We are pleased to announce this latest
product approval. Diltiazem is used to treat high blood pressure
and to control chest pain (angina). Akorn expects to launch
Diltiazem in the fourth quarter." About Akorn, Inc. Akorn, Inc.
manufactures and markets sterile specialty pharmaceuticals. Akorn
has manufacturing facilities located in Decatur, Illinois and
Somerset, New Jersey and markets and distributes an extensive line
of hospital and ophthalmic pharmaceuticals. Additional information
is available at the Company's website at www.akorn.com. Materials
in this press release may contain information that includes or is
based upon forward-looking statements within the meaning of the
Securities Litigation Reform Act of 1995. Forward-looking
statements give our expectations or forecasts of future events. You
can identify these statements by the fact that they do not relate
strictly to historical or current facts. They use words such as
"anticipate," "estimate," "expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning in
connection with a discussion of future operating or financial
performance. In particular, these include statements relating to
future steps we may take, prospective products, future performance
or results of current and anticipated products, sales efforts,
expenses, the outcome of contingencies such as legal proceedings,
and financial results. Any or all of our forward-looking statements
here or in other publications may turn out to be wrong. They can be
affected by inaccurate assumptions or by known or unknown risks and
uncertainties. Many such factors will be important in determining
our actual future results. Consequently, no forward-looking
statement can be guaranteed. Our actual results may vary
materially, and there are not guarantees about the performance of
our stock. Any forward-looking statements represent our
expectations or forecasts only as of the date they were made and
should not be relied upon as representing our expectations or
forecasts as of any subsequent date. We undertake no obligation to
correct or update any forward-looking statements, whether as a
result of new information, future events or otherwise, even if our
expectations or forecasts change. You are advised, however, to
consult any further disclosures we make on related subjects in our
reports filed with the SEC. In particular, you should read the
discussion in the section entitled "Cautionary Statement Regarding
Forward-Looking Statements" in our most recent Annual Report on
Form 10-K, as it may be updated in subsequent reports filed with
the SEC. That discussion covers certain risks, uncertainties and
possibly inaccurate assumptions that could cause our actual results
to differ materially from expected and historical results. Other
factors besides those listed there could also adversely affect our
results.
Grafico Azioni Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (AMEX:AKN)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Safety First Trust Principal-Protected Trust Certificates Linked TO A U.S.-Europe-Japan Basket Structured Product (Borsa Americana (AMEX)): 0 articoli recenti
Più Akorn, Inc. Articoli Notizie